Elsner, Leslie
Heimann, Lisanne
Geisler, Anja
Dieringer, Babette
Knoch, Klaus-Peter
Hinze, Luisa
Klingel, Karin
Solimena, Michel
Kurreck, Jens
Fechner, Henry
Funding for this research was provided by:
Technische Universität Berlin
Article History
Received: 4 March 2024
Accepted: 12 April 2024
First Online: 25 April 2024
Declarations
:
: The animal experiments were performed in accordance with the principles of laboratory animal care and all German laws regarding animal protection and approved by the responsible local authorities (State Office of Health and Social Affairs, Berlin, Germany, reference number G 0048/18).
: Not applicable.
: HF has a patent for oncolytic CVB3 PD. HF and LE have a patent pending for use of the adaptation protocol to generate OV.